Quanterix (QTRX) and Akoya Biosciences (AKYA) said Friday they entered into a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction.
Under the agreement, which was approved by both companies' boards, Akoya shareholders will receive 0.318 Quanterix shares for each Akoya share, reflecting a 19% premium based on Akoya's stock price on Nov. 14, 2024, according to the companies.
The transaction is expected to close in Q2, after which Quanterix shareholders will own 70% of the combined entity, while Akoya shareholders will hold 30%, on a fully diluted basis, and the merged company will continue to operate under the Quanterix name, the companies said.
Quanterix's Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will continue to hold the same roles at the merged entity, whose new board will include nine members, with two directors joining from Akoya's current board.
Shares of Akoya and Quanterix jumped more than 35% and 9%, respectively, in recent premarket activity.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。